Casp8ap2 antagonists for use in the prevention or treatment of cancer
AssigneesAlbert-Ludwigs-Universität Freiburg, Deutsches Krebsforschungszentrum
InventorsSven Diederichs, Ksenia Myacheva
Life of this patent
Estimating the term…
Abstract
The present invention provides the use of a CASP8AP2 antagonist in the prevention or treatment of cancer. Preferably, the antagonist reduces the viability of the cancer cells without significantly reducing the viability of normal cells in the subject to be treated. Further, methods of treatment and pharmaceutical compositions suitable in said methods are provided, as well.
Claims15
A Caspase-8 associated protein-2 (CASP8AP2) antagonist for use in the prevention or treatment of cancer, with the proviso that the CASP8AP2 antagonist is not a peptide comprising the amino acid sequence SMMPDELLTSL (SEQ ID NO:
- 140) or a peptide comprising the amino acid sequence KLDKNPNQV (SEQ ID NO:141).
A method for identifying a CASP8AP2 antagonist comprising
- i) screening a test compound for binding to CASP8AP2 protein;
- ii) optionally determining in vitro the caspase-mediated apoptotic activity induced by the test compound identified in step i) in a cancer cell line, wherein the caspase is selected from caspase-3/7, caspase-8 and caspase-9;
- and
- iii) selecting the test compound as a CASP8AP2 antagonist if the test compound binds to CASP8AP2 and optionally increases the apoptotic activity of Caspase-3/7 and/or Caspase-8 and/or Caspase-9 compared to the caspase-mediated apoptotic activity in the absence of the test compound.
A method for identifying a CASP8AP2 antagonist comprising
- i) screening a test compound for binding to CASP8AP2 protein;
- and
- ii) optionally determining in vitro the cell viability of a cancer cell induced by the test compound identified in step i);
- and
- iii) selecting the test compound as a CASP8AP2 antagonist if the test compound binds to CASP8AP2 and optionally reduces the cell viability of the cancer cell compared to the cell viability of the cancer cell in the absence of the test compound.
Dependencies are inferred from the claim text.